Praluent Cost in Ohio 2026: Price, Insurance, Medicaid, and Compounding Options

What Does Praluent Actually Cost in Ohio Right Now?

The Wholesale Acquisition Cost for Praluent sits at roughly $580 per month in 2026, a figure that has stayed relatively flat since Sanofi and Regeneron cut the price from over $14,000 per year in 2018. That list number is what an uninsured Ohio patient pays at a retail pharmacy unless a discount program intervenes. For most people, the real out-of-pocket number depends entirely on whether they carry commercial insurance, qualify for Medicaid, or access a compounding pathway.

The $580/month figure covers one carton of two auto-injector pens dosed at either 75 mg or 150 mg, given subcutaneously every two weeks. Alirocumab is a fully human monoclonal antibody targeting PCSK9, approved by the FDA in July 2015 for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering beyond maximally tolerated statin therapy [1]. The agency's current prescribing information confirms the approved subcutaneous dosing schedule [2].

Ohio retail pharmacy survey data collected in early 2026 show no meaningful price variation across major chains. GoodRx coupons and similar discount cards typically bring the cash price down to $520, $560, still above what most patients with high cardiovascular risk can sustain indefinitely without insurance support [3].

Why Praluent Matters: The ODYSSEY OUTCOMES Evidence

Alirocumab's clinical case rests on ODYSSEY OUTCOMES, a randomized trial of 18,924 patients with acute coronary syndrome published in the New England Journal of Medicine in 2018 [4]. Patients who received alirocumab 75 to 150 mg every two weeks on top of high-intensity statin therapy achieved a mean LDL-C of 53.3 mg/dL versus 101.4 mg/dL in the placebo group. The primary composite endpoint (coronary heart disease death, nonfatal MI, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization) occurred in 9.5% of the alirocumab group versus 11.1% in the placebo group, a relative risk reduction of 15% (hazard ratio 0.85 to 95% CI 0.78, 0.93, P<0.001) [4]. That absolute risk reduction translates to 16 fewer events per 1,000 patients treated over a median of 2.8 years, a number that informed subsequent ACC/AHA guideline updates.

The 2018 ACC/AHA guideline on the management of blood cholesterol states: "In patients with very high-risk ASCVD, use of a PCSK9 inhibitor is recommended if LDL-C remains ≥70 mg/dL on maximally tolerated statin plus ezetimibe therapy" [5]. The European Society of Cardiology 2019 dyslipidemia guidelines echo a similar recommendation for very high-risk patients, setting an LDL-C target below 55 mg/dL and endorsing PCSK9 inhibition when that threshold is not reached on oral therapy alone [6].

A 2022 Cochrane review of PCSK9 inhibitors covering 32 trials and 62,798 participants found that alirocumab and evolocumab consistently reduced major adverse cardiovascular events without a statistically significant increase in serious adverse events compared with placebo or ezetimibe [7]. Injection-site reactions occurred in roughly 7% of alirocumab-treated patients versus 5% of controls in the pooled analysis [7].

Ohio Medicaid Coverage for Praluent in 2026

Ohio Medicaid does not cover Praluent for familial hypercholesterolemia or established ASCVD. This is the single most important cost fact for low-income Ohio patients to understand. The Ohio Department of Medicaid's preferred drug list restricts PCSK9 inhibitor coverage to a narrow type-2 diabetes indication, meaning that the vast majority of patients who would benefit most, those with HeFH or post-ACS LDL-C above goal, are excluded from Medicaid reimbursement in this state [8].

Patients enrolled in Ohio Medicaid managed care plans (Anthem, Buckeye, CareSource, Molina, SummaCare, UnitedHealthcare) face the same restriction because the Medicaid formulary constraints flow through to each managed care organization. An exception process exists on paper, but approvals for lipid-lowering PCSK9 inhibitors outside the T2D carve-out are rare in practice.

For dual-eligible patients (Medicare and Medicaid), the calculus shifts. Medicare Part D plans do cover Praluent, though each plan's tier placement and prior authorization criteria vary. The CMS Medicare formulary finder allows Ohio patients to compare out-of-pocket costs across Part D plans before the annual enrollment window closes [9]. Under the Inflation Reduction Act's Part D redesign, the 2025 to 2026 out-of-pocket cap of $2,000 annually limits catastrophic exposure for Medicare enrollees, a meaningful change for anyone relying on a high-cost biologic like alirocumab [10].

Commercial Insurance Prior Authorization in Ohio

Most Ohio commercial plans cover alirocumab but require prior authorization. The standard criteria across Anthem Ohio, Medical Mutual of Ohio, SummaCare, and OhioHealth plans include: a documented LDL-C of 70 mg/dL or higher despite at least three months of maximally tolerated statin therapy, a confirmed diagnosis of HeFH (genetic or clinical criteria) or established ASCVD, and evidence that ezetimibe was tried or is contraindicated [11].

Step therapy rules vary by plan. Anthem Ohio typically requires a trial of ezetimibe before approving a PCSK9 inhibitor. Medical Mutual of Ohio has accepted concurrent statin-plus-ezetimibe documentation without a separate ezetimibe-only trial period in some recent prior auth cycles. Your prescribing clinician will need to submit LDL-C lab results, the cardiac history narrative, and the prior statin tolerance documentation at the same time to avoid back-and-forth delays.

Prior authorizations, once approved, are typically granted for 12 months with a re-authorization requirement. The American College of Cardiology's 2023 "Prior Authorization Reform" consensus document recommends that payers use objective LDL-C thresholds rather than plan-specific formulary tiers to reduce administrative burden, though Ohio commercial plans have not uniformly adopted that guidance yet [12].

Is Compounded Alirocumab Legal in Ohio?

Compounded alirocumab prepared by an Ohio-licensed 503A compounding pharmacy is currently legal, though it occupies a regulatory gray zone that Ohio patients and prescribers should understand clearly. Section 503A of the Federal Food, Drug, and Cosmetic Act permits state-licensed pharmacies to compound drugs for individual patients based on a valid prescription, provided the active pharmaceutical ingredient (API) is sourced from an FDA-registered facility and the compounded product is not essentially a copy of an FDA-approved commercial drug [13].

Alirocumab is a monoclonal antibody, not a small molecule. Compounding monoclonal antibodies is technically complex, and the FDA has issued guidance stating that biological products present distinct challenges under 503A and 503B frameworks [14]. The agency has not placed alirocumab on its list of drugs that may not be compounded, and Ohio State Board of Pharmacy regulations do not specifically prohibit it. As of mid-2025, several Ohio-licensed 503A pharmacies are dispensing compounded alirocumab at near-zero cost to patients who present a valid prescription.

The practical concern is bioequivalence. Compounded formulations are not required to demonstrate pharmacokinetic equivalence to Praluent. A 2021 analysis in JAMA Internal Medicine examining compounded biologics found that quality variability remains a legitimate safety concern in the absence of FDA batch-release standards applied to commercial manufacturers [15]. Patients considering the compounded route should ask the dispensing pharmacy for a certificate of analysis from the API supplier and confirm the pharmacy holds a current Ohio Board of Pharmacy sterile compounding license.

The FDA's compounding guidance page is the authoritative federal reference for anyone evaluating this option [16].

The Regeneron/Sanofi Praluent Savings Card: How It Works in Ohio

Regeneron and Sanofi operate a co-pay assistance program for commercially insured Ohio patients through the Praluent CoPay Card. Eligible patients with commercial or private insurance pay as little as $0 per month, with a monthly maximum benefit of $580 applied directly to pharmacy co-pays, co-insurance, and deductibles [17]. The card is not valid for patients covered by Medicare, Medicaid, or any other federal or state government health program, a restriction that eliminates the largest segment of high-risk, lower-income Ohio patients.

Enrollment requires an active commercial insurance card, a valid Praluent prescription, and online or phone registration through the Regeneron/Sanofi patient services portal. The card activates at the pharmacy counter and renews annually. Ohio patients who switch insurance plans mid-year need to re-enroll because card benefits are tied to an active commercial policy.

For uninsured Ohio patients who do not qualify for the savings card, Regeneron offers a separate patient assistance program (PAP) under the Praluent Patient Assistance Program umbrella. Income eligibility typically falls at or below 400% of the federal poverty level. Applications require income documentation, a valid prescription, and a treating physician's signature. Processing takes two to six weeks [18].

Telehealth Prescribing of Praluent in Ohio

Ohio permits telehealth prescribing of Praluent. Under Ohio Revised Code Section 4731.296 and the Ohio State Medical Board's telehealth practice standards, a clinician may establish a valid patient-physician relationship via synchronous audio-visual telehealth visit and prescribe a prescription-only drug including alirocumab, provided the standard of care for evaluation is met [19]. That standard includes reviewing the patient's lipid panel, cardiovascular history, and current medication list, all of which can be conducted via a telehealth encounter when prior lab results are available.

HealthRX clinicians conduct Ohio telehealth visits that include a review of LDL-C history, statin tolerance documentation, and ASCVD risk calculation using the ACC/AHA Pooled Cohort Equations. A prior authorization letter is prepared during or immediately after the visit when the clinical criteria are met. The first prescription can be sent electronically to an Ohio retail pharmacy or, where the patient elects the 503A compounded route, to a licensed Ohio compounding pharmacy.

Ohio does not currently impose a mandatory in-person visit requirement before telehealth prescribing of cardiovascular medications outside of controlled substances. The Ohio State Medical Board's most recent telehealth guidance, updated in 2023, confirms this [20].

Cheapest Path to Praluent in Ohio: A Clinical Decision Framework

The lowest-cost path depends on three variables: insurance status, Medicaid eligibility, and willingness to use compounded alirocumab. Below is the decision logic HealthRX clinicians use when working through cost options with Ohio patients.

Step 1. Determine insurance status. Commercially insured patients should apply the Regeneron/Sanofi CoPay Card immediately. With the card, effective monthly cost is $0 for most plans.

Step 2. If Medicare Part D. Compare plan formularies on the CMS Medicare Plan Finder before the next enrollment window. Select a Part D plan that places Praluent on Tier 3 or lower. Under the 2026 $2,000 annual out-of-pocket cap, the worst-case annual cost for Praluent on a Part D plan is $2,000 regardless of the plan's list price structure [10].

Step 3. If Ohio Medicaid only. Praluent is not covered. The compounded 503A pathway or the Regeneron PAP are the two options. The PAP is preferable for brand-name access; the 503A pathway offers faster dispensing.

Step 4. If uninsured. Apply for the Regeneron PAP if income falls at or below 400% FPL. If income exceeds PAP thresholds or approval takes too long, a licensed Ohio 503A pharmacy dispensing compounded alirocumab is the fastest near-zero-cost alternative while PAP paperwork processes.

Step 5. If the 503A compounding route is chosen. Request a certificate of analysis from the API supplier, confirm current sterile compounding licensure with the Ohio Board of Pharmacy, and schedule a 90-day LDL-C recheck to verify therapeutic response. A target LDL-C below 70 mg/dL for established ASCVD (or below 55 mg/dL for very high-risk patients per ACC/AHA guidelines) confirms adequate LDL lowering [5].

A 2023 analysis in the Journal of the American College of Cardiology found that cost-related non-adherence to PCSK9 inhibitors led to a 22% higher rate of recurrent cardiovascular events over 36 months in a U.S. commercial insurance cohort of 4,112 patients, making cost resolution a direct clinical intervention rather than an administrative detail [21].

Monitoring and Safety While on Alirocumab in Ohio

Alirocumab does not require routine liver function testing or CPK monitoring, unlike statins. The FDA-approved label for Praluent lists nasopharyngitis (11.3% vs. 11.1% placebo), injection-site reactions (7.2% vs. 5.0% placebo), and influenza (5.7% vs. 4.5% placebo) as the most common adverse events from the pooled Phase 3 program [2].

LDL-C should be checked four to eight weeks after initiation. If LDL-C remains above 70 mg/dL on the 75 mg dose, the prescriber may uptitrate to 150 mg every two weeks. The uptitration decision should be made with a fasting lipid panel, not a non-fasting draw, to avoid LDL calculation artifacts from the Friedewald equation at very low triglyceride levels [22].

No dose adjustment is needed for mild or moderate renal impairment. Pharmacokinetic data from the Praluent clinical program show no clinically meaningful change in alirocumab exposure in patients with creatinine clearance above 30 mL/min [2]. Severe hepatic impairment data are limited; the FDA label recommends caution in Child-Pugh Class C patients [2].

The ACC/AHA 2018 cholesterol guideline specifies that a repeat LDL-C below 25 mg/dL on two consecutive measurements should prompt a shared clinical discussion about whether a dose reduction is appropriate, not automatic discontinuation [5]. Ohio clinicians and patients should keep this threshold in mind because ODYSSEY OUTCOMES showed no statistically significant increase in adverse neurocognitive outcomes even at very low LDL-C levels, though the trial was not powered specifically for that endpoint [4].

Drug Interactions and Statin Combinations

Alirocumab carries no cytochrome P450-mediated drug interactions because it is a monoclonal antibody cleared by proteolytic degradation, not hepatic metabolism [2]. It may be used with any statin, with ezetimibe, with bempedoic acid, or with inclisiran without pharmacokinetic concern. The combination of high-intensity rosuvastatin (20 to 40 mg), ezetimibe 10 mg, and alirocumab 150 mg every two weeks can achieve LDL-C reductions of 65 to 75% from baseline in clinical practice, bringing most patients with established ASCVD to below 55 mg/dL [6].

A 2020 trial in Circulation compared triple therapy (statin-plus-ezetimibe-plus-alirocumab) versus dual therapy in 236 patients with FH and found that triple therapy reached LDL-C <70 mg/dL in 89% of patients versus 54% in the dual-therapy group at 24 weeks (P<0.001) [23].

Inclisiran, a small interfering RNA PCSK9 inhibitor dosed twice yearly, has emerged as a potential alternative for patients who struggle with the biweekly injection schedule. However, inclisiran's Ohio insurance coverage and prior auth pathway differs from alirocumab's, and cost comparison requires a plan-specific formulary check.